Blurbs

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Autolus Therapeutics (AUTL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNXResearch Report) and Autolus Therapeutics (AUTLResearch Report).

RegenXBio (RGNX)

Wedbush analyst Andreas Argyrides maintained a Hold rating on RegenXBio today and set a price target of $32.00. The company’s shares closed last Thursday at $34.74.

According to TipRanks.com, Argyrides has 0 stars on 0-5 stars ranking scale with an average return of -24.8% and a 20.8% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and BioMarin Pharmaceutical.

RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $47.00, representing a 42.4% upside. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $47.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Autolus Therapeutics (AUTL)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Thursday at $3.05.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.5% and a 34.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $13.00 average price target, which is a 343.7% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $12.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RGNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos